Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1354
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 157–168 of 1,354 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Not applicable Interventional

Ultrasonic Debris Clearance to Promote Brain Resilience

NCT07573982
Status at this site: Recruiting
View directory record Official record
Conditions
Alzheimer s Disease, MCI With Increased Risk for Alzheimer Disease
Interventions
Ultrasonic Debris Clearance, sham
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 3 Interventional

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions
Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
63
States / cities
Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Not applicable Interventional

Zenith® Fenestrated+ Clinical Study

NCT04875429
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Interventions
Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

NCT05993949
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoblastic Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 3 Interventional

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759
Status at this site: Recruiting
View directory record Official record
Conditions
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions
Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus, Samuraciclib, PH FDC SC, Palbociclib, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Duarte, California • Irvine, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
Site status not listed — check the official record
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions
Radiation Therapy, Temozolomide, Veliparib
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
145
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine (ASTX727), Venetoclax
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
24
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Recruiting No phase listed Observational

Measuring Surgical Recovery After Radical Cystectomy

NCT03193970
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Bladder Cancer
Interventions
Post-Operative Recovery Registry
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

MHE3 Clinical Trial - Overcoming Obstacles

NCT06712147
Site status not listed — check the official record
View directory record Official record
Conditions
Mental Health Services, Community Mental Health Services, Community Health Services, Preventive Health Services, Counseling, Community Networks, Community Participation, Hispanic or Latino
Interventions
Overcoming Life's Hurdles: Mental health education, Overcoming Life's Hurdles: Resources in the community
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 10:38 AM EDT

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.